Balyasny Asset Management LLC Pacira Bio Sciences, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 434,206 shares of PCRX stock, worth $11.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
434,206Holding current value
$11.2 Million% of portfolio
0.01%Shares
12 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$206 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$135 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$84 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$58.1 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$51.3 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.18B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...